Order Article Reprints

Maeoka R, Nakazawa T, Matsuda R, Morimoto T, Shida Y, Yamada S, Nishimura F, Nakamura M, Nakagawa I, Park Y-S, et al. Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom. International Journal of Molecular Sciences. 2023; 24(18):14183. https://doi.org/10.3390/ijms241814183

Maeoka, Ryosuke, Tsutomu Nakazawa, Ryosuke Matsuda, Takayuki Morimoto, Yoichi Shida, Shuichi Yamada, Fumihiko Nishimura, Mitsutoshi Nakamura, Ichiro Nakagawa, Young-Soo Park, and et al. 2023. "Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom" International Journal of Molecular Sciences 24, no. 18: 14183. https://doi.org/10.3390/ijms241814183

Maeoka, R., Nakazawa, T., Matsuda, R., Morimoto, T., Shida, Y., Yamada, S., Nishimura, F., Nakamura, M., Nakagawa, I., Park, Y.-S., Tsujimura, T., & Nakase, H. (2023). Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom. International Journal of Molecular Sciences, 24(18), 14183. https://doi.org/10.3390/ijms241814183